Publications by authors named "Weeke P"
Background: Heart failure with mildly reduced or preserved ejection fraction (hereafter referred to as HFpEF) is the most common type of heart failure and is associated with a high risk of hospitalisation and death, especially in patients with overweight, obesity, or type 2 diabetes. In the STEP-HFpEF and STEP-HFpEF DM trials, semaglutide improved heart failure-related symptoms and physical limitations in participants with HFpEF. Whether semaglutide also reduces clinical heart failure events in this group remains to be established.
View Article and Find Full Text PDFBackground: Patients with overweight and obesity are at increased risk of death from multiple causes, including cardiovascular (CV) death, with few therapies proven to reduce the risk.
Objectives: This study sought to assess the effect of semaglutide 2.4 mg on all-cause death, CV death, and non-CV death, including subcategories of death and death from coronavirus disease-2019 (COVID-19).
Article Synopsis
- Semaglutide, a GLP-1 receptor agonist used for weight loss, may lower the risk of serious cardiovascular issues in individuals with obesity, but its specific effects on those with pre-existing heart conditions, like atherosclerotic cardiovascular disease and heart failure, were unclear.
- The SELECT trial, a comprehensive study involving adult participants with cardiovascular disease and high BMI, examined the impact of weekly injections of semaglutide versus placebo on heart-related outcomes, particularly focusing on those with varying types of heart failure.
- Researchers looked for differences in cardiovascular events, analyzing data to see if treatment efficacy and safety were affected by heart failure type and participants’ initial health characteristics.
Objective: To evaluate the cardiovascular effects of semaglutide by baseline glycated hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT).
Research Design And Methods: In SELECT, people with overweight or obesity and atherosclerotic cardiovascular disease without diabetes were randomized to weekly semaglutide 2.4 mg or placebo.
The prevalence and impact of perioperative atrial fibrillation (AF) during an admission for major emergency abdominal surgery are sparsely examined. Therefore, this study aimed to compare the 30-day and 1-year outcomes (AF-related hospitalization, stroke, and all-cause mortality) in patients with and without perioperative AF to their major emergency abdominal surgery. All patients without a history of AF who underwent major emergency abdominal surgery from 2000 to 2019 and discharged alive were identified using Danish nationwide registries.
View Article and Find Full Text PDFArticle Synopsis
- - The study examined the effectiveness of cardiac resynchronization therapy (CRT) among immigrants and non-immigrants in Denmark, focusing on heart failure-related hospitalizations and overall mortality from 2000 to 2017.
- - Results showed that both groups experienced similar improvements in hospitalizations after CRT, but there was no significant difference in five-year mortality rates overall, although Middle Eastern immigrants had higher mortality compared to non-immigrants.
- - The majority of deaths in both groups were due to cardiovascular issues, indicating that while CRT was effective for both populations, certain demographics may face increased risks post-therapy.
Background: Patients with chronic renal failure on hemodialysis carry a significant risk of infective endocarditis (IE), but data on whether these patients differ from other patients with IE in terms of comorbidity, microbiology, rates of surgery and mortality are sparse.
Methods: Using Danish nationwide registries, all patients with IE diagnosed between February 1, 2010, and May 14, 2018 were identified and categorized into a "hemodialysis group" and a "non-hemodialysis group." Patient groups were compared by comorbidities, microbiological etiology, cardiac surgery, and mortality.
Background: Valve-in-valve-transcatheter aortic valve implantation (TAVI) is a feasible and increasingly used treatment option for failed surgical aortic prosthesis, but data from clinical practice are limited. We aimed to examine patient characteristics and outcomes of patients undergoing TAVI in a surgival valve (valve-in-valve TAVI) compared with patients undergoing TAVI in a native valve.
Methods: Using nationwide registries, we identified all Danish citizens, who underwent TAVI from January 1, 2008, to December 31, 2020.
Article Synopsis
- The study investigates the relationship between Brugada syndrome (BrS) diagnosis and the development of new-onset depression or anxiety, as well as all-cause mortality among patients over a follow-up period of up to 5 years.
- Out of 223 patients identified with BrS, 15.7% developed new-onset depression or anxiety, with symptomatic patients showing a higher incidence compared to asymptomatic ones.
- The findings suggest that factors like symptomatic disease presentation and older age are significantly linked to an increased risk of developing mental health issues in BrS patients, although overall mortality rates were low.
Aims: While clinical trials have suggested that a high ventricular rate is associated with increased risk of heart failure (HF) and mortality, all-comers studies are warranted.
Objective: To assess 1-year risk of new-onset diagnosed HF and all-cause mortality among rate-control treated patients presenting with atrial fibrillation (AF) on an electrocardiogram (ECG) according to ventricular rate.
Methods And Results: ECGs recorded at the Copenhagen General Practitioners Laboratory (2001-15) were used to identify patients with AF.
Aim: To examine temporal changes in incidence rates of atrial fibrillation/flutter (AF), treatment strategies, and AF readmission rates in patients <65 years.
Methods: Using Danish nationwide registries, we identified patients <65 years with a first-time AF diagnosis from 2000 to 2018. The cohort was categorized according to calendar periods; 2000-2002, 2003-2006, 2007-2010, 2011-2014, and 2015-2018.
Article Synopsis
- About one-third of patients diagnosed with Brugada syndrome (BrS) were treated with nonrecommended medications, with no significant change in prescription patterns observed post-diagnosis.
- Female patients, those with psychiatric diseases, and those with prior use of nonrecommended drugs were more likely to use these medications after diagnosis.
- No significant associations were found between nonrecommended drug use and outcomes like appropriate implantable cardioverter defibrillator therapy, mortality, or arrhythmic events during follow-up.
Objectives: We examined loop diuretic treatment before and 1-year after transcatheter aortic valve implantation (TAVI), as a proxy for changes in symptom severity and secondly assessed how changes in loop diuretics related to mortality risk.
Background: Randomized clinical trials suggest that approximately one third of patients undergoing TAVI do not achieve symptom relief, but "all-comer" data are lacking.
Methods: Using Danish nationwide registries, we identified all citizens, who underwent TAVI from 2008 to 2019 and were alive at 1-year post-discharge.
Aims: Thyroid dysfunction is considered the most frequent complication to amiodarone treatment, but data on its occurrence outside clinical trials are sparse. The present study aimed to examine the incidence of thyroid dysfunction following initiation of amiodarone treatment in a nationwide cohort of patients with and without heart failure (HF).
Methods And Results: In Danish registries, we identified all patients with first-time amiodarone treatment during the period 2000-18, without prior thyroid disease or medication.
Article Synopsis
- The study aimed to evaluate the risk of developing malignant arrhythmias, specifically torsades de pointes (TdP), related to certain drugs in patients who experienced out-of-hospital cardiac arrest (OHCA).
- Researchers analyzed data from the Danish Cardiac Arrest Registry, focusing on patients 18 and older with a cardiac origin OHCA between 2001 and 2014, determining the prevalence and impact of TdP risk drug usage on patient outcomes.
- Findings showed that 37% of patients were treated with TdP risk drugs shortly before OHCA, which correlated with a decreased likelihood of experiencing a shockable rhythm and achieving return of spontaneous circulation (ROSC), although these patients tended to be older and more comorbid
Background: Ethnicity might impact out-of-hospital cardiac arrest (OHCA) risk, but it has scarcely been studied in Europe. We aimed to assess whether ethnicity influenced the risk of OHCA of cardiac cause in Danish immigrants and its interplay with risk factors for OHCA and socioeconomic status.
Methods: This nationwide study included all immigrants between 18 and 80 years present in Denmark at some point between 2001 and 2020.
Article Synopsis
- The study investigates workforce attachment of patients with congenital long QT syndrome (cLQTS) in Denmark from 1996 to 2016, focusing on their employment status post-diagnosis.
- It finds that over 90% of cLQTS patients remained employed one year after their diagnosis, similar to a matched control group, but with a slight drop in attachment compared to the general population.
- Severe manifestations of the condition, such as aborted cardiac arrests, significantly increase the likelihood of workforce detachment within that year.
Background: The incidence rates and importance of traditional risk factors in dilated cardiomyopathy among first-degree relatives are unknown.
Methods And Results: We identified all probands with dilated cardiomyopathy (n = 13,714, mean age at diagnosis 63 years) from the Danish nationwide registries between 1994 and 2017. Incidence rates among first-degree relatives (n = 29,671, mean age 38 years) and for up to 10 age- and sex-matched controls were calculated.
β-blocker adherence among patients with congenital long QT syndrome: a nationwide study.
Eur Heart J Qual Care Clin Outcomes
December 2022
Aim: β-blockers are the first line of treatment in patients with congenital long QT syndrome (cLQTS) (class I or II recommendation) in order to prevent malignant arrhythmias. Hence, we examined long-term β-blocker adherence and associated risk factors among patients with cLQTS.
Methods And Results: Danish patients with cLQTS claiming a prescription for any β-blocker after their cLQTS diagnosis were identified using data from nationwide registries and specialized inherited cardiac disease clinics (1995-2017).
Return to work after acute myocardial infarction with cardiogenic shock: a Danish nationwide cohort study.
Eur Heart J Acute Cardiovasc Care
June 2022
Background: Physical and mental well-being after critical illness may be objectified by the ability to work. We examined return to work among patients with myocardial infarction (MI) by cardiogenic shock (CS) status.
Methods: Danish nationwide registries were used to identify patients with first-time MI by CS status between 2005 and 2015, aged 18-63 years, working before hospitalization and discharged alive.
Background Oral anticoagulation (OAC) is effective for stroke prevention in patients with atrial fibrillation. However, some patients experience stroke despite OAC therapy, and knowledge about the impact of prior treatment quality is lacking. Methods and Results Patients with atrial fibrillation on OAC therapy who had a first-time ischemic stroke were identified in the Danish Stroke Registry (2005-2018).
View Article and Find Full Text PDFBackground: Acquired long QT syndrome (aLQTS) is a serious unpredictable adverse drug reaction. Pharmacogenomic markers may predict risk.
Methods: Among 153 aLQTS patients (mean age 58 years [range, 14-88], 98.
Background: Ergot-derived dopamine agonists are thought to induce fibrotic changes in cardiac valve leaflets. We sought to determine the incidence of heart valve disease in women treated with bromocriptine compared with age and sex matched controls from the background population.
Methods: In nationwide Danish registries we identified female patients treated with bromocriptine in the period 1995-2018.